Stay updated on 177Lu-DOTA-rosopatamab vs SoC in PSMA+ mCRPC: Clinical Trial

Sign up to get notified when there's something new on the 177Lu-DOTA-rosopatamab vs SoC in PSMA+ mCRPC: Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the 177Lu-DOTA-rosopatamab vs SoC in PSMA+ mCRPC: Clinical Trial page

  1. Check
    2 days ago
    No Change Detected
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    Change Detected
    Summary
    The page indicates an updated ClinicalTrials.gov interface/revision version in the footer (moving to v3.5.3). This is a site-level version change and does not alter the study record details shown on the page.
    Difference
    0.1%
    Check dated 2026-04-24T05:55:03.000Z thumbnail image
  4. Check
    23 days ago
    Change Detected
    Summary
    Revision: v3.5.2 was added, replacing the previous v3.5.0.
    Difference
    0.1%
    Check dated 2026-04-17T02:42:49.000Z thumbnail image
  5. Check
    52 days ago
    Change Detected
    Summary
    - Revision updated from v3.4.3 to v3.5.0.
    Difference
    0.1%
    Check dated 2026-03-19T05:05:25.000Z thumbnail image
  6. Check
    59 days ago
    Change Detected
    Summary
    A new revision entry v3.4.3 was added to the record history. The previous revision v3.4.2 was removed from the history.
    Difference
    0.1%
    Check dated 2026-03-12T00:29:07.000Z thumbnail image
  7. Check
    73 days ago
    Change Detected
    Summary
    Telix is conducting a separate Phase 3 trial (NCT06520345) under an IND, which necessitates the closure of the current 177Lu-TLX591-002 Phase 3 trial. The record now shows the study as Terminated and indicates that the prior Recruiting status was removed.
    Difference
    1.0%
    Check dated 2026-02-25T18:52:32.000Z thumbnail image
  8. Check
    88 days ago
    Change Detected
    Summary
    New system Revision: v3.4.2 has been added to the record history, and the prior government funding lapse notice has been removed.
    Difference
    0.9%
    Check dated 2026-02-11T12:37:59.000Z thumbnail image

Stay in the know with updates to 177Lu-DOTA-rosopatamab vs SoC in PSMA+ mCRPC: Clinical Trial

Enter your email address, and we'll notify you when there's something new on the 177Lu-DOTA-rosopatamab vs SoC in PSMA+ mCRPC: Clinical Trial page.